glp-1 warnings The growing availability of compounded weight-loss drugs has prompted from doctors and the U.S. Food and Drug Administration GLP-1RA Essentials in Gastroenterology: Side

So it makes a lot of sense to ban them

The brand qualifies this with the following: results vary based on starting weight and program adherence, individual results are not typical and may vary, claims are based on self-reported customer data rather than clinical trials, and medication prescriptions are at the discretion of medical providers

Ozempic is the name brand for the generic drug "semaglutide." Ozempic is approved for Type 2 Diabetes, while its sister drug Wegovy is approved for Obesity, for the prevention of recurrent cardiovascular disease, and for people with kidney disease

Members received notification in fall 2025 with an effective date of January 1, 2026